Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Spartan Capital Securities, LLC and B2i Digital Announce the Spartan Capital Investor Conference 2024
-
CV Sciences, Inc. Reports Second Quarter 2024 Financial Results
-
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
-
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update
-
Iterum Therapeutics Announces Expiration and Results of Rights Offering
-
Beneficient Joins B2i Digital Family of Featured Companies
-
Spartan Capital Securities, LLC and B2i Digital Announce the Spartan Capital Investor Conference 2024
-
Spartan Capital Securities, LLC and B2i Digital Announce the Spartan Capital Investor Conference 2024
-
Citius Pharmaceuticals (CTXR) Announces TenX Keane Shareholder Approval of Merger with Citius Oncology
-
TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals
-
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
-
SELLAS Life Sciences (SLS) Announces 15.85M Share Offering at $1.325/sh
-
SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
-
Roadzen Inc. (RDZN) PT Lowered to $7 at Maxim Group
-
Heart Test Laboratories Inc. (HSCS) PT Lowered to $12 at Maxim Group
-
BWX Technologies (BWXT) PT Lowered to $113 at Maxim Group
-
Beyond Inc. (BYON) PT Lowered to $33 at Maxim Group
-
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
-
OrangeKloud Technology Inc. Announces Closing of $13.1 Million Initial Public Offering
-
CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering
-
Chemomab Therapeutics (CMMB) Announces $10 Million Private Placement
-
Chemomab Therapeutics Announces $10 Million Private Placement
-
OrangeKloud Technology (ORKT) Prices 2.75M Share IPO at $4.75/sh
-
OrangeKloud Technology Inc. Announces Pricing of $13.1 Million Initial Public Offering
-
NBA signs broadcasting deal with Disney, Amazon, Comcast worth $77 billion
-
Azitra, Inc (AZTR) Prices 6.66M Share Offering at $1.50/sh
-
Azitra, Inc. Announces Pricing of $10.0 Million Public Offering
-
Rani Therapeutics (RANI) Prices 2.8M Share Offering at $3.08/sh Registered Direct Offering
-
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering
-
Iterum Therapeutics (ITRM) Commences Rights Offering
-
Iterum Therapeutics Commences Rights Offering
-
PSI and AIB Acquisition Complete Business Combination
-
Nicolet Bankshares (NIC) PT Raised to $120 at Maxim Group
-
Icon Energy Corp. Announces Closing of $5.0 Million Initial Public Offering
-
Kolibri Global Energy Inc. Announces Shareholder Loyalty Campaign in Partnership with TiiCKER and B2i Digital
-
Kolibri Global Energy Inc. Announces Shareholder Loyalty Campaign in Partnership with TiiCKER and B2i Digital
-
Icon Energy Corp (ICON) Prices 1.25M Share IPO at $4/sh
-
Icon Energy Corp. Announces Listing on Nasdaq and Pricing of $5.0 Million Initial Public Offering
-
Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”
-
ReShape Lifesciences Inc. (RSLS) to Merge with Vyome Therapeutics, Enters Asset Purchase Agreement With Biorad Medisys
-
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
-
Eureka Acquisition Corp Announces Closing of $50 Million Initial Public Offering
-
Eureka Acquisition Corp Announces Pricing of $50 Million Initial Public Offering
-
Nexalin Technology Announces Closing of $5.2 Million Public Offering
-
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
-
Brainstorm Cell Therapeutics (BCLI) Prices 11.11M Share Offering at $0.36/sh
-
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
-
Rezolute (RZLT) Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
-
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
-
Maxim Group starts MicroStrategy (MSTR) at Buy on AI opportunity, Bitcoin play

